

Covalon Announces First Time Attendance At The 32nd Annual Oley Consumer/Clinician Conference

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Jul. 6, 2017-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be exhibiting for the first time at the 32nd Annual Oley Consumer/Clinician Conference taking place at the Hyatt Regency in Old Greenwich, CT from July 5-8, 2017.

In addition to exhibiting, Covalon will sponsor a presentation by Brenda Gray, PharmD, CNSC, BCNSP, PRS CVAA(c) entitled *Medical Adhesive-Related Skin Injuries (MARSI), how consumers can prevent and manage its occurrence* on July 7, 2017 at 2:45pm and 4pm in Salon Cos Cob.

Medical adhesive-related skin injury is a clinically relevant and potentially avoidable event. Preventing MARSI has the potential to reduce complications, increase patient satisfaction, and improve clinical outcomes.¹

Covalon's IV Clear™ is indicated to cover and protect vascular access devices used in a wide variety of both acute and alternate care settings. Its patented combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most commonly associated blood stream infection bacteria² and its skin sparing silicone adhesive will not cause adhesive related skin injury or pain during dressing changes³.

"As proud first time sponsors of this event, and are excited about the opportunity to show patients and their clinicians the combined benefits that only IV Clear can offer," said John R. Hands, Executive Vice President.

The Oley Foundation is a national, independent, non-profit organization that strives to enrich the lives of patients dependent on home intravenous nutrition (parenteral) and tube feeding (enteral) through education, advocacy, and networking. The Foundation also serves as a resource for consumer's families, clinicians and industry representatives, and other interested parties.

To learn more about IV Clear, visit Covalon at booth 23 during exhibit hours, or email ivclear@covalon.com

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

1 Farris M, K, et al. Medical Adhesive-Related Skin Injury Prevalence Among Adult Acute Care Patients. *J Wound Ostomy Continence Nurs.* 2015;42(6):589-598.

2 A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. *American Journal of Infection Control* , Volume 43 , Issue 6 , S22

3 A Human Repeat Patch Test Study, DiTizio et al. <http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters>

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170706005697/en/>

Source: Covalon Technologies Ltd.

Covalon Technologies Ltd.

Brian Pedlar, 905-568-8400 x 233

CEO

bpedlar@covalon.com

Toll free: 1.877.711.6055

www.covalon.com

Twitter: @covalon

<https://ir.covalon.com/press-releases?item=159>